Progenics Pharmaceuticals, Inc. (PGNX)


Stock Price Forecast

June 19, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Progenics Pharmaceuticals, Inc. chart...

About the Company

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Sector

Health Technology

Industry

Biotechnology

Employees

105

CEO

David W. Mims

Exchange

NASDAQ

Website

http://www.progenics.com

$37M

Total Revenue

105

Employees

$353M

Market Capitalization

-5.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PGNX News

Elite Pharmaceuticals, Inc. (ELTP)

1d ago, source: Yahoo Finance

Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...

Acurx Pharmaceuticals, Inc. (ACXP)

1d ago, source: Yahoo Finance

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the ...

Fidelity Management & Research Co. 3Q 13F: Largest Eliminations

1mon ago, source: ADVFN

Company Name Ticker Change PROGENICS PHARMACEUTICALS INC PGNX (8,503,246) HEALTH MANAGEMENT ASSOCIATES HMA (6,703,002) CHIQUITA BRANDS INTERNATIONAL CQB (6,476,636) PDL BIOPHARMA INC COM PDLI ...

Alnylam Pharmaceuticals

4d ago, source: Forbes

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Regeneron Pharmaceuticals Inc.

1y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PMVP PMV Pharmaceuticals, Inc.

14d ago, source: Seeking Alpha

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...

Vertex Pharmaceuticals Inc VRTX

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ANI Pharmaceuticals Inc ANIP

1d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

XENE Xenon Pharmaceuticals Inc.

1d ago, source: Seeking Alpha

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical ...

Rocket Pharmaceuticals, Inc.

5mon ago, source: CNN

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi ...

Madrigal Pharmaceuticals, Inc.

4mon ago, source: CNN

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...